Teva announces data from PEARL study on AJOVY in migraine prevention

Teva Pharmaceutical announces further data from the pan-European PEARL study investigating the impact of AJOVY on the prevention of migraine in a real-world setting, due to be completed in 2024. The data from the 3rd interim analysis reveals that almost 60% of patients achieved a greater than or equal to50% reduction in monthly migraine days from baseline for migraine prevention, with sustained improvement in disability scores and acute medication use observed over 12 months. Treatment persistence rates were high, with 82.3% of patients remaining on treatment by month 12. Not only was fremanezumab effective in preventing migraine attacks in patients with chronic and episodic migraine, but it has also shown to be effective in reducing the severity and duration of remaining migraine attacks. Four abstracts from the third interim analysis of the PEARL study will be presented at the 9th European Academy of Neurology Congress in Budapest, Hungary. The primary analysis is being presented as an oral presentation by Professor Cristina Tassorelli, Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy on July 1, 2023.